Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIconic Labs Regulatory News (ICON)

Share Price Information for Iconic Labs (ICON)

Share Price is delayed by 15 minutes
Get Live Data
1.70    0.10 (6.25%)
Bid:
1.55
Ask:
1.85
Spread: 0.30 (19.355%)
Market Cap: £264.88k
ICON Live PriceLast checked at - London Stock Exchange

Intraday Iconic Labs Share Chart

Financing Facility

22 Dec 2022 09:02

RNS Number : 6132K
Iconic Labs PLC
22 December 2022
 

The announcement set out below was published on the Company's website on 28 September 2022 but due to an oversight it was not published through RNS at the time.

 

 

28 September 2022

 

Iconic Labs Plc ("Iconic") In Administration

 

Iconic Enters into £3 million Financing Facility with EHGO

 

Iconic Labs Plc (LSE:ICON), is pleased to announce that on 28 September 2022 it entered into a £3 million Deed of Issuance and Subscription in respect of loan notes ("Notes") convertible into new ordinary shares with share subscription warrants ("Warrants") attached (together "the Financing Facility") with the European High Growth Opportunities Securitization Fund ("EHGO").

 

Iconic intends to drawdown on the Financing Facility in up to 14 sequential tranches over a maximum period of 18 months. Each Note has a duration of 24 months as from its date of issue.

 

Today Iconic submitted a drawdown notice to EHGO for the first tranche of £250,000. The subsequent tranches will be as follows: (i) £150,000 for tranches 2 through 6; and (ii) £250,000 for tranches 7 through 14. 

 

Under the Financing Facility, EHGO will provide Iconic with up to £3 million by subscribing for up to 3,000 Notes, each with a par value of £1,000, convertible into new ordinary shares in the Company, with the Warrants attached. Each Note is convertible into shares of Iconic at a conversion price equal to highest of a) 90% of the lowest volume-weighted average price of the 15 trading days prior to delivery of a conversion notice and b) the nominal value of the shares. Iconic is to pay a commitment fee of £ 150,000 in Notes under the terms of the Financing Facility. On termination of the Financing Facility Iconic has an obligation to pay EHGO an administration fee in the total aggregate amount of twenty percent (20%) of the principal amount of all Notes outstanding at the time of the termination.

 

The Financing Facility is subject to Iconic complying with certain obligations and conditions precedent, including:

 

· With respect to the fourth tranche onwards, that the suspension on Iconic's shares from trading on the London Stock Exchange be lifted within 3 months of the agreement being entered into, and that the shares of Iconic recommence trading on Main Market of the London Stock Exchange (the "Commencement of Trading");

 

· From the first tranche following the Commencement of Trading onwards:

o the closing market price of the shares for each of the ten consecutive trading days falling immediately prior to the relevant closing date must be at least higher than 150% of the nominal value of Iconic's shares; and

o the average daily value traded of Iconic's shares (excluding 5% of the data points from the top and excluding 5% of the data points from the bottom of the data set) for the 20 trading days immediately prior to the applicable closing date must be at least £ 10,000;

 

· From the fifth Tranche onwards, Iconic having published a prospectus;

 

· No binding commitment having been entered into by Iconic pursuant to which a change of control in Iconic would occur; and

 

· No occurrence that constitutes an event of default having occurred and is continuing.

 

The Warrants will amount to 50% of the financing provided by EHGO such that the number of Warrants will be equal to 50% of the principal amount of the Notes divided by the warrant exercise price.

 

Before the trading suspension on Iconic's shares is lifted and trading resumes, the warrant exercise price will be equal to the share price immediately prior to suspension, or £0.00016 per share.

 

If the trading suspension in Iconic's shares is lifted and trading resumes, the warrant exercise price will be equal to 120% of the share volume weighted average price of the shares over the 15 trading days immediately preceding the relevant subscription or issuance request.

 

Iconic will only be able to draw down on the first three tranches, for a total of £550,000, prior to the trading suspension in Iconic's shares being lifted by the Financial Conduct Authority and Iconic is once again trading on the Main Market of the London Stock Exchange. The Iconic executive team, advisors and auditors are diligently working to have the trading suspension lifted as soon as possible. Iconic will provide updates on its progress in due course.

 

**ENDS**

For further information, please visit the Company's website www.iconiclabs.co.uk or contact:

Iconic Labs ir@iconiclabs.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEFEISAEEESEIE
Date   Source Headline
30th Oct 20184:25 pmRNSNotice of AGM
30th Oct 20182:05 pmRNSSecond Price Monitoring Extn
30th Oct 20182:00 pmRNSPrice Monitoring Extension
30th Oct 20187:00 amRNSWideacademy Restructuring
29th Oct 20184:33 pmRNSHolding(s) in Company
23rd Oct 20188:27 amRNSConversion of Bond
22nd Oct 20183:27 pmRNSConversion of bonds
22nd Oct 20187:00 amRNSSmart Cells Deal
19th Oct 20189:20 amRNSHolding(s) in Company
18th Oct 201812:47 pmRNSBoard Restructuring
17th Oct 20184:48 pmRNSHolding(s) in Company
1st Oct 201811:00 amRNSPrice Monitoring Extension
28th Sep 20183:30 pmRNSHolding(s) in Company
27th Sep 20184:40 pmRNSSecond Price Monitoring Extn
27th Sep 20184:35 pmRNSPrice Monitoring Extension
27th Sep 201810:40 amRNSNotification of transactions of Directors
27th Sep 20187:10 amRNSInterim Results
27th Sep 20187:00 amRNSFinancing Agreement
30th Jul 20187:00 amRNSCellPlan Launch in Spain
9th Jul 20187:01 amRNSBoard Changes
9th Jul 20187:00 amRNSHolding(s) in Company
29th Jun 20183:00 pmRNSResult of AGM
28th Jun 201810:30 amRNSResult of General Meeting
15th Jun 20187:00 amRNSAlign Research Initiation of Coverage
12th Jun 20186:25 pmRNSProspectus and Notice of General Meeting
11th Jun 20189:00 amRNSLive Market Bookbuild Closes
11th Jun 20187:30 amRNSRestoration Widecells Group Plc
11th Jun 20187:00 amRNSUpdate Regarding Placing and Financial Position
6th Jun 20183:00 pmRNSNotice of AGM
5th Jun 20187:00 amRNSAudited Preliminary Results
21st May 20187:00 amRNSFinal Results Update
10th May 201810:30 amRNSPlacing to Raise £1.47m and Live Market Bookbuild
3rd May 20187:30 amRNSSuspension Widecells Group
1st May 20187:02 amRNSAnnual Accounts and Fundraising Update
26th Mar 20187:00 amRNSLandmark deal to launch CellPlan insurance in Asia
19th Mar 20187:00 amRNSGranted Innovate UK KTP for Stem Cell Research
27th Feb 20187:00 amRNSLicence Award from the Human Tissue Authority
19th Feb 20187:00 amRNSBoard Changes and Launch of Wideacademy Platform
21st Dec 20177:00 amRNSCorporate Update
2nd Nov 20177:00 amRNSRevenue generation with White Apex agreement
12th Oct 20177:00 amRNSCellPlan expansion, e-commerce platform launch UK
11th Oct 20177:00 amRNSPartner Secured to Expand into MENA & Asia-Pacific
29th Sep 20177:00 amRNSInterim Results
25th Sep 20177:00 amRNSWideacademy Update, Presenting at Investor Event
15th Aug 20177:00 amRNSRaises £750,000 to support Company's divisions
31st Jul 20177:00 amRNSResearch Licence Granted from HTA
24th Jul 20177:00 amRNSNew product to target the dental market
21st Jul 20177:00 amRNSCellPlan launches E-Commerce Platform in the UK
12th Jul 20177:00 amRNSCorporate Charity Commitment
4th Jul 20177:00 amRNSAgreement to Roll Out CellPlan in Brazil

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.